These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10973873)

  • 1. Effects of chronic renal failure and hemodialysis on the monoethylglycinexylidide liver function test.
    Palatini P; Floreani M; Padrini R; Piccoli P; Bertoli M; Calò L; Orlando R
    Clin Chem; 2000 Sep; 46(9):1406-8. PubMed ID: 10973873
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of lidocaine in patients with renal failure.
    Collinsworth KA; Strong JM; Atkinson AJ; Winkle RA; Perlroth F; Harrison DC
    Clin Pharmacol Ther; 1975 Jul; 18(1):59-64. PubMed ID: 1149363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of lidocaine metabolite formation as a quantitative liver function test in children.
    Gremse DA; A-Kader HH; Schroeder TJ; Balistreri WF
    Hepatology; 1990 Sep; 12(3 Pt 1):565-9. PubMed ID: 2401461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test.
    Huang YS; Chiang JH; Wu JC; Chang FY; Lee SD
    Am J Gastroenterol; 2002 May; 97(5):1223-7. PubMed ID: 12014732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
    Muñoz AE; Miguez C; Rubio M; Bartellini M; Levi D; Podestá A; Niselman V; Terg R
    Dig Dis Sci; 1999 Apr; 44(4):789-95. PubMed ID: 10219840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lidocaine monoethylglycinexylidide test of liver function.
    Ghent CN; Wall WJ
    Liver Transpl Surg; 1996 May; 2(3):242-5. PubMed ID: 9346657
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dynamic liver function study using the lidocaine test].
    Sídlová K; Průsa R
    Cas Lek Cesk; 2000 Sep; 139(19):604-5. PubMed ID: 11192753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects.
    Reichel C; Nacke A; Sudhop T; Wienkoop G; Lüers C; Hahn C; Pohl C; Spengler U; Sauerbruch T
    Hepatology; 1997 Jun; 25(6):1323-7. PubMed ID: 9185746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis.
    Elin RJ; Fried MW; Sampson M; Ruddel M; Kleiner DE; DiBisceglie AM
    Clin Chem; 1997 Oct; 43(10):1952-7. PubMed ID: 9342018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans.
    Schütz E; Shipkova M; Armstrong VW; Oellerich M
    Hepatology; 1998 Nov; 28(5):1439-40. PubMed ID: 9794937
    [No Abstract]   [Full Text] [Related]  

  • 12. Sensitive HPLC for simultaneous quantification of lidocaine and its metabolites monoethylglycinexylidide and glycinexylidide in serum.
    O'Neal CL; Poklis A
    Clin Chem; 1996 Feb; 42(2):330-1. PubMed ID: 8595734
    [No Abstract]   [Full Text] [Related]  

  • 13. [Liver function tests in patients with terminal renal failure treated conservatively and with repeated hemodialysis].
    Smoleński O; Caban M; Kutrzeba W
    Pol Tyg Lek; 1980 Feb; 35(8):273-5. PubMed ID: 7360704
    [No Abstract]   [Full Text] [Related]  

  • 14. [Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].
    Kupcová V; Turecký L; Szántová M; Schmidtová K
    Bratisl Lek Listy; 1999 Jan; 100(1):12-24. PubMed ID: 10492993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
    Testa R; Borzone S; Campo N; Alvarez S; Caglieris S; Arzani L; Risso D; Lantieri PB; Celle G
    Transplant Proc; 1994 Dec; 26(6):3624-5. PubMed ID: 7998297
    [No Abstract]   [Full Text] [Related]  

  • 16. Clearance of lidocaine by hemodialysis.
    Vaziri ND; Saiki JK; Hughes W
    South Med J; 1979 Dec; 72(12):1567-8. PubMed ID: 515769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renal failure and hemodialysis on cephacetrile pharmacokinetics.
    Nissenson AR; Levin NW; Parker RH
    Clin Pharmacol Ther; 1972; 13(6):887-94. PubMed ID: 5081601
    [No Abstract]   [Full Text] [Related]  

  • 18. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
    Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
    Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate dosing of pilsicainide hydrochloride in patients on hemodialysis.
    Matsumoto M; Fujii Z; Kawata Y; Sakumura T; Minami M; Fujimoto K; Nawata C; Matsuzaki M
    Nephron; 2001 Jun; 88(2):134-7. PubMed ID: 11399915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin half-life in normal and impaired renal function.
    Perry PJ; Herron GR; King JC
    Clin Pharmacol Ther; 1974 Sep; 16(3):514-9. PubMed ID: 4413659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.